SHIELD THERAPEUTICS PLC (STX) — Full year trading update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SHIELD THERAPEUTICS PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And now I'd I'd now like to hand you over to Anders Lundstrom, CEO. Good afternoon, sir. Good afternoon, and good morning, depending on where you are. Welcome to the quarter four and full year twenty twenty four trading update for SHIELD THERAPEUTICS. I'll start, and then Santos Schrambach will continue. Our CFO will continue after a little bit. So this is the disclaimer. So so SHIELD THERAPEUTICS, we have a product called AccraFer in The US or Feracru in in Europe, and it's it's, indicated and approved for treating oral iron, deficiency with or without anemia. And And it's a very broad indication, so it doesn't matter what the person or patient's underlying condition, is is leading to the, iron deficiency. The US market is a very big market as we will show you in a little bit, and and that's why we also chosen to commercialize on our own together with a partner, Viatris. We estimate The US to have a revenue potential for Aquifer. It could be up to $450,000,000 annually, and we have very, very strong IP through 2035. So this is our management team. We divide it up in two offices. So David and Jackie are in in Newcastle in The United Kingdom, and the rest of us are are jus...